Trial Profile
Phase 1, Open-label, Single Sequence, Two-Period Crossover Trial to Evaluate the Effect of Tepotinib on CYP3A by Investigating the PK of the CYP3A Substrate Midazolam in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Tepotinib (Primary) ; Midazolam
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 27 Nov 2018 Status changed from not yet recruiting to completed.
- 21 Aug 2018 New trial record